NOTOC__ For patient information click [[{{PAGENAME}} (patient information),here]] {{Renal cell carcinoma}} {{CMG}}; {{AE}} {{YD}}, {{SSK}}, {{SC}} {{SK}} RCC; Renal cell CA; Kidney cancer; Kidney carcinoma; Kidney CA; Grawitz tumor; Hypernephroma ==[[Renal cell carcinoma overview,Overview]]== ==[[Renal cell carcinoma historical perspective,Historical Perspective]]== ==[[Renal cell carcinoma classification,Classification]]== ==[[Renal cell carcinoma pathophysiology,Pathophysiology]]== ==[[Renal cell carcioma causes,Causes]]== ==[[Renal cell carcinoma differential diagnosis,Differentiating Renal cell carcinoma from other Diseases]]== ==[[Renal cell carcinoma epidemiology and demographics,Epidemiology and Demographics]]== ==[[Renal cell carcinoma risk factors,Risk Factors]]== ==[[Renal cell carcinoma screening,Screening]]== ==[[Renal cell carcinoma natural history, complications, and prognosis,Natural History, Complications and Prognosis]]== ==Diagnosis== [[Renal cell carcinoma ...
Headline: Bitcoin & Blockchain Searches Exceed Trump! Blockchain Stocks Are Next!. Metastatic Renal Cell Carcinoma market report covers research informatics related to Metastatic Renal Cell Carcinoma clinical trials, such as a listing of industry and sponsored clinical trials as well as new drug therapies.. Designed to be a resource both for patients interested in participating in Metastatic Renal Cell Carcinoma clinical trials and for research professionals.. The report, "Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016″ provides an overview of Metastatic Renal Cell Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Metastatic Renal Cell Carcinoma. Report includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.. Browse ...
TY - JOUR. T1 - Vagina as a rare location of renal cell carcinoma metastasis. AU - Ladjevic, I. L.. AU - Stefanovic, A.. AU - Kadija, S.. AU - Terzic, M.. AU - Jeremic, K.. AU - Janjic, T.. PY - 2016/1/1. Y1 - 2016/1/1. N2 - Introduction: Metastatic renal cell carcinoma is often found in distant organs, including lung, bone, brain,and liver. Metastases to the vagina are extremely rare. Case Report: The authors present a case of renal cell carcinoma metastasis to the anterior vaginal wall four months after nephrectomy in a 56-year-old patient. The vaginal lesions were excised. After two years the patient had no signs of recurrence or the disease progression. Conclusion: Vaginal metastases should be considered in differential diagnosis of female renal cell carcinoma patients presenting with vaginal bleeding of mass.. AB - Introduction: Metastatic renal cell carcinoma is often found in distant organs, including lung, bone, brain,and liver. Metastases to the vagina are extremely rare. Case Report: ...
List of Tables. Table 1: Clinical subtypes of Indication. Table 2: Risk Factors. Table 3: Prevalence cases (%) Region wise. Table 4: Sources used for forecasting the data. Table 5: Renal cell carcinoma Global Epidemiology, (2013-2023). Table 6: Prevalent Cases of Renal cell carcinoma (Ages =XX Years), US (2013-2023). Table 7: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), US (2013-2023). Table 8: Prevalent Cases By Renal cell carcinoma Sub-population, US (2013-2023). Table 9: Prevalent Cases of Renal cell carcinoma (Ages =XX Years), United Kingdom (2013-2023). Table 10: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), United Kingdom (2013-2023). Table 11: Prevalent Cases By Renal cell carcinoma Sub-population, United Kingdom (2013-2023). Table 12: Prevalent Cases of Renal cell carcinoma (Ages =XX Years), Germany (2013-2023). Table 13: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), Germany (2013-2023). Table 14: Prevalent Cases By Renal cell ...
Title:Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC). VOLUME: 8 ISSUE: 3. Author(s):Zofia F. Bielecka, Anna M. Czarnecka, Wojciech Solarek, Anna Kornakiewicz and Cezary Szczylik. Affiliation:Laboratory of Molecular Oncology, Department of Oncology, Military Institute of Medicine in Warsaw, Szaserów 128, 04-141 Warsaw, Poland.. Keywords:Acquired drug resistance, tyrosine kinase inhibitors, sunitinib, sorafenib, pazopanib, axitinib, tivozanib, epithelialmesenchymal transition, angiogenic switch, anti-angiogenic therapy, clear-cell renal cell carcinoma, non-genetic resistance mechanisms.. Abstract:Clear - cell renal cell carcinoma (ccRCC) is a histological subtype of renal cell carcinoma - the most prevalent adult kidney cancer. Causes of ccRCC are not completely understood and therefore number of available therapies is limited. As a consequence of tumor chemo- and radioresistance as well as restrictions in offered targeted therapies, ...
Sumanta Pal, MD of City of Hope, Duarte, CA, discusses the introduction of new data of the new single-agent cabozantinib for advanced renal cell carcinoma. The agent is a dual MET and VEGFR2 inhibitor, and has been assessed in metastatic renal cell carcinoma and other diseases. Dr Pal highlights his involvement in the Phase I trials of cabozantinibs development in renal cell carcinoma, where impressive responses were observed. He proceeds to highlight that most recently, cabozantinib was used in a Phase III METEOR trial comparing it to the agent everolimus (NCT01865747). This study identified an improvement in response rate, overall survival (OS) and progression-free survival (PFS) for patients with advanced renal cell carcinoma. According to Dr Pal, these findings make the agent the optimal second-line choice in patients with metastatic renal cell carcinoma. He further adds that data from the CABOSUN study (NCT01835158), a clinical trial that compared sunitinib and cabozantinib in the front-line
TY - JOUR. T1 - In search of a better crystal ball. T2 - Recent advances in prognostic markers for clear-cell renal cell carcinoma. AU - Shah, Jay B.. AU - Margulis, Vitaly. PY - 2010/6. Y1 - 2010/6. N2 - Advances in imaging have led to a steady increase in the incidence of kidney cancer over the last two decades. There has been no corresponding improvement in our ability to predict the behavior of renal cell carcinoma. Patients with low-risk renal cell carcinoma have good long-term survival with only localized therapy but patients with aggressive disease do poorly, even with optimal multimodal treatment. Biomarkers to differentiate between these two very divergent populations have traditionally been of only limited utility. We review the recent advances in the development of molecular and immunologic markers aimed at improving prognostication of renal cell carcinoma.. AB - Advances in imaging have led to a steady increase in the incidence of kidney cancer over the last two decades. There has ...
Metachronous renal cell carcinoma after radical nephrectomy is extremely rare. Renal cell carcinoma commonly metastasizes to distant organs. However, metastasis to the urinary bladder is very uncommon. Herein, we report a case of metachronous renal cell carcinoma with metastasis to the urinary bladder, left acetabulum, left rib, lungs, thyroid, right renal vein and inferior vena cava. The patient had undergone a left-sided radical nephrectomy 28 years ago. The pathological diagnosis of a fragment of the bladder tumor was consistent with Fuhrman grade 2 clear cell renal cell carcinoma. Although metachronous renal cell carcinoma after radical nephrectomy is rare, active surveillance should be still considered. Renal cell carcinoma has shown to unusually metastasize to the urinary bladder, a rarely reported organ of metastasis. Treatment options, such as immunotherapy, are available to patients with such metastasis and long-term survivorship can be achieved.
Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2 David M Gill1†, David D Stenehjem2†, Kinjal Parikh3, Jo
TY - JOUR. T1 - Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study. AU - Stroup, Sean P.. AU - Raheem, Omer A.. AU - Palazzi, Kerrin L.. AU - Liss, Michael A.. AU - Mehrazin, Reza. AU - Kopp, Ryan P.. AU - Patel, Nishant. AU - Cohen, Seth A.. AU - Park, Samuel K.. AU - Patterson, Anthony L.. AU - Kane, Christopher J.. AU - Millard, Frederick. AU - Derweesh, Ithaar H.. PY - 2013/4. Y1 - 2013/4. N2 - Objective: To compare outcomes of metastatic renal cell carcinoma (mRCC) patients who underwent primary cytoreductive nephrectomy (CRN), followed by adjuvant sunitinib therapy, vs those who underwent primary sunitinib therapy before planned CRN. Methods: This was a multi-institutional retrospective analysis of 35 mRCC patients from June 2005 to August 2009 (median follow-up, 28.5 months): 17 underwent primary CRN, followed by adjuvant sunitinib (group 1); 18 underwent primary sunitinib ...
This paper presents the conclusions of a workshop entitled Impact of Molecular Genetics on the Classification of Renal Cell Tumours, which was held in Heidelberg in October 1996. The focus on renal cell tumours excludes any discussion of Wilms tumour and its variants, or of tumours metastatic to the kidneys. The proposed classification subdivides renal cell tumours into benign and malignant parenchymal neoplasms and, where possible, limits each subcategory to the most commonly documented genetic abnormalities. Benign tumours are subclassified into metanephric adenoma and adenofibroma, papillary renal cell adenoma, and renal oncocytoma. Malignant tumours are subclassified into common or conventional renal cell carcinoma; papillary renal cell carcinoma; chromophobe renal cell carcinoma; collecting duct carcinoma, with medullary carcinoma of the kidney; and renal cell carcinoma, unclassified. This classification is based on current genetic knowledge, correlates with recognizable histological ...
TY - JOUR. T1 - Cloning of renal cell carcinoma relation gene. T2 - Construction of a cDNA subtractive library of human renal cell carcinoma and its significance. AU - Zhang, Qiang. AU - Mao, Ze Bin. AU - Zhang, Zhi Wen. AU - Xin, Dian Qi. AU - Guo, Ying Lu. PY - 2000/12/1. Y1 - 2000/12/1. N2 - To construct a cDNA subtractive library of human renal cell carcinoma (RCC) with technique called suppression subtractive hybridization. The library only contains the differently expressing cDNAs between RCC and normal kidney. Poly (A)+ RNA were isolated from cell lines of RCC and normal kidney respectively. Moreover, single-strand cDNAs and double-strand cDNAs were synthesized in turn. After enzyme restriction, cDNAs between 400600 bp were obtained. RCC cDNAs then were divided into two groups and ligated to the specific adaptor 1 and adaptor 2 respectively . After RCC cDNAs hybridized with normal kidney cDNA twice and underwent two times of nested PCR, then with arms of T/A plasmid vectors to set up the ...
Clear cell renal cell carcinoma is a complex disease with only partial response to therapy and scarce reliable clinical parameters indicative of progression and survival. Fibroblast activation protein expression has been correlated with prognosis in several malignancies but never in renal cancer. We aim to analyze the immunohistochemical expression of fibroblast activation protein in 208 clear cell renal cell carcinomas and to evaluate its impact on the prognosis and survival. A positive cytoplasmic immunostaining of this protein in the stromal fibroblasts associated to cancer cells is associated with large tumor diameter (≥ 4 cm), high-grade (G3/4) tumors, and high-stage (≥ pT3) tumors. Fibroblast activation protein-positive cases had significantly shorter survivals after 5 (P = .00015), 10 (P = .0000042), and 15 (P = .000043) years of follow-up, with a hazard ratio of 0.31. Multivariate analysis showed that fibroblast activation protein (P = .00117) was stronger than grade and stage in ...
TY - JOUR. T1 - Alterations in chromatin accessibility and DNA methylation in clear cell renal cell carcinoma. AU - Buck, M. J.. AU - Raaijmakers, L. M.. AU - Ramakrishnan, S.. AU - Wang, D.. AU - Valiyaparambil, S.. AU - Liu, S.. AU - Nowak, N. J.. AU - Pili, Roberto. PY - 2014/10/9. Y1 - 2014/10/9. N2 - Recent studies have demonstrated that in clear cell renal cell carcinoma (ccRCC) several chromatin remodeling enzymes are genetically inactivated. Although, growing evidence in cancer models has demonstrated the importance of epigenetic changes, currently only changes in DNA methylation can be accurately determined from clinical samples. To address this limitation, we have applied formaldehyde-assisted isolation of regulatory elements (FAIREs) combined with next-generation sequencing (FAIRE-seq) to identify specific changes in chromatin accessibility in clinical samples of ccRCC. We modified the FAIRE procedure to allow us to examine chromatin accessibility for small samples of solid tumors. ...
Human Kidney Slide (Clear Cell Renal Cell Carcinoma) (5 slides/pk) Slide for IHC HTS-10405 Human Kidney Slide (Clear Cell Renal Cell Carcinoma) (5 slides/pk) Slide for IHC HTS-10405
Background:It has been suggested that the apparent protective effect of alcohol intake on renal cell carcinoma may be due to the diluting effect of carcinogens by a high total fluid intake. We assessed the association between intakes of total fluids and of specific beverages on the risk of renal cell carcinoma in a large prospective cohort of UK women.Methods:Information on beverage consumption was obtained from a questionnaire sent 3 years after recruitment into the Million Women Study. Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) for renal cell carcinoma associated with beverage consumption adjusted for age, region of residence, socioeconomic status, smoking, and body mass index.Results:After an average of 5.2 years of follow-up, 588 cases of renal cell carcinoma were identified among 779 369 women. While alcohol intake was associated with a reduced risk of renal cell carcinoma (RR for 2 vs 1 drink per day: 0.76; 95% CI: 0.61-0.96; P for
Clear cell renal cell carcinoma (ccRCC) is the most common pathological subtype of renal cell carcinoma, and immune-related genes (IRGs) are key contributors to its development. In this study, the gene expression profiles and clinical data of ccRCC patients were downloaded from The Cancer Genome Atlas database and the cBioPortal database, respectively. IRGs were obtained from the ImmPort database. We analyzed the expression of IRGs in ccRCC, and discovered 681 that were differentially expressed between ccRCC and normal kidney tissues. Univariate Cox regression analysis was used to identify prognostic differentially expressed IRGs (PDEIRGs). Using Lasso regression and multivariate Cox regression analyses, we detected seven optimal PDEIRGs (PLAU, ISG15, IRF9, ARG2, RNASE2, SEMA3G and UCN) and used them to construct a risk model to predict the prognosis of ccRCC patients. This model accurately stratified patients with different survival outcomes and
TY - JOUR. T1 - Acquired cystic disease associated renal cell carcinoma. AU - Bakkannavar, Shankar M.. AU - Velayudhan, Dewaraj. AU - Prabhu, Ravindra. AU - Ramnarayan, K.. PY - 2018/1/1. Y1 - 2018/1/1. N2 - Acquired cystic disease predisposes to renal cell carcinoma. We describe a patient who had received kidney transplant 7 years back with normal allograft function who suffered sudden cardiac death at home and was discovered to have acquired cystic disease and renal cell carcinoma in her native kidneys. This case highlights the need to assess native kidneys periodically after kidney transplant.. AB - Acquired cystic disease predisposes to renal cell carcinoma. We describe a patient who had received kidney transplant 7 years back with normal allograft function who suffered sudden cardiac death at home and was discovered to have acquired cystic disease and renal cell carcinoma in her native kidneys. This case highlights the need to assess native kidneys periodically after kidney ...
Through combined deletion of Vhl, Trp53 and Rb1 in renal epithelial cells, the authors develop a new mouse model of renal cell carcinoma that recapitulates the cellular and molecular features of a large proportion of human tumors. This model uncovers a role for primary-cilium-related genes in the development of the disease and provides a reliable platform for preclinical therapeutic studies. Clear cell renal cell carcinomas (ccRCCs) frequently exhibit inactivation of the von Hippel-Lindau tumor-suppressor gene, VHL, and often harbor multiple copy-number alterations in genes that regulate cell cycle progression. We show here that modeling these genetic alterations by combined deletion of Vhl, Trp53 and Rb1 specifically in renal epithelial cells in mice caused ccRCC. These tumors arose from proximal tubule epithelial cells and shared molecular markers and mRNA expression profiles with human ccRCC. Exome sequencing revealed that mouse and human ccRCCs exhibit recurrent mutations in genes associated with
Bristol-Myers Squibb has announced the early closure of its phase 3 CheckMate-025 trial evaluating nivolumab (Opdivo) compared with everolimus for the treatment of previously-treated patients with advanced or metastatic renal cell carcinoma.. The study was stopped early because an independent Data Monitoring Committee assessment found that nivolumab is superior to everolimus in this patient population.. "The results of CheckMate-025 mark the first time an Immuno-Oncology agent has demonstrated a survival advantage in advanced renal cell carcinoma, a patient group that currently has limited treatment options," said Michael Giordano, senior vice president, Head of Development, Oncology, Bristol-Myers Squibb. "Through our Opdivo clinical development program, we aim to redefine treatment expectations for patients with advanced RCC by providing improved survival.". For the open-label trial, 821 previously-treated patients with advanced or metastatic clear-cell renal cell carcinoma were randomly ...
TY - JOUR. T1 - Axial Abdominal Imaging after Partial Nephrectomy for T1 Renal Cell Carcinoma Surveillance. AU - Sorokin, Igor. AU - Canvasser, Noah E.. AU - Margulis, Vitaly. AU - Lotan, Yair. AU - Raj, Ganesh. AU - Sagalowsky, Arthur I. AU - Gahan, Jeffrey. AU - Cadeddu, Jeffrey A. PY - 2017. Y1 - 2017. N2 - Purpose: The overall recurrence rate of T1 renal cell carcinoma is low. We evaluated abdominal imaging after partial nephrectomy based on current guidelines for T1 renal cell carcinoma surveillance. Materials and Methods: We retrospectively reviewed the records of patients with T1 renal cell carcinoma who underwent partial nephrectomy between 2006 and 2012 followed by abdominal imaging at our institution. Primary and secondary outcomes were the incidence and timing, respectively, of imaging diagnosed abdominal recurrences. A literature review was performed to summarize prior reports of recurrence incidence and timing after partial nephrectomy for T1 disease. Results: A total of 160 ...
Background and objective: Clear Cell Renal Cell Carcinoma (CCRCC) is the most common adult renal neoplasm. Staging and grading of RCC are important predictors of survival. Fuhrman nuclear grading is widely used for CCRCC, the subjective nature of which has prompted more objective methods to evaluate nuclear features. Furthermore, Ki-67, a reliable marker of cellular proliferation may provide another variable for assessment of the biological behavior of RCC. The aim of this research was to study nuclear morphometry and Fuhrman nuclear grading of clear cell RCC, and to assess their relationship with the Ki-67 index. Methods: Hematoxylin and eosin slides of forty cases of CCRCC were retrieved and studied for pathologic variables, including Fuhrman nuclear grade, pathological tumor and node stage. Nuclear morphometric analysis was performed using computer-assisted image analysis. The relationship between Fuhrman nuclear grading, pathologic stage, tumor size, nuclear morphometry and proliferative index were
ABSTRACT. Cell cycle regulation in human renal cell carcinoma. Ylva Hedberg, Departments of Medical Biosciences, Pathology, and Surgical and. Perioperative Sciences, Urology Andrology, Umeå University, Sweden. Deregulated growth control is a hallmark of neoplasia potentially caused by aberrant expression of cell cycle regulatory proteins. The importance of such aberrations in human renal cell carcinoma (RCC) has not been fully clarified. Therefore, the protein expressions of several G1/S regulatory proteins in human RCC were evaluated and their relation to clinico-pathological data was examined.. Western blotting and immunohistochemistry were used to detect the proteinexpression of cyclin D1, D3, and E in 80 RCCs. Most tumors expressed higher levels of cyclin D1 (75%) and cyclin E (65%) compared to corresponding normal kidney cortex. In contrast, only 16 % of the tumors had high levels of cyclin D3. In conventional RCCs, low levels of cyclin D1 were associated with large tumor size, aneuploidy ...
TY - JOUR. T1 - A case of sarcomatoid renal cell carcinoma (RCC) with lower GI bleeding. AU - Salwa, Siti M.S.. AU - Firdaus, Mohd C.A.. AU - Goh, Eng Hong. AU - Tan, Guan Hee. AU - Singam, Praveen. AU - Fam, Xeng Inn. PY - 2017/7/1. Y1 - 2017/7/1. UR - http://www.scopus.com/inward/record.url?scp=85032032940&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=85032032940&partnerID=8YFLogxK. M3 - Letter. AN - SCOPUS:85032032940. VL - 22. SP - 152. EP - 153. JO - Surgical Chronicles. JF - Surgical Chronicles. SN - 1108-5002. IS - 3. ER - ...
The results of a phase III trial comparing two commonly used drugs in the second-line treatment of renal cell carcinoma suggest that temsirolimus does not improve survival over sorafenib in the second line setting.. The two drugs inhibit different targets: temsirolimus targets mTOR, which regulates cell growth and proliferation, while sorafenib inhibits several tyrosine kinases, including VEGF receptors.. This is the first head-to-head phase III trial comparing a VEGF inhibitor to an mTOR inhibitor in renal cell carcinoma, reporting final results. Hence, this trial will have important treatment implications for patients and physicians, noted Dr Thomas Hutson from Texas Oncology-Baylor Charles A Sammons Cancer Center in Texas, USA.. Temsirolimus had demonstrated an overall survival benefit compared to interferon alfa in previously untreated patients with advanced renal cell carcinoma and poor prognostic features, but the drugs efficacy after treatment with a VEGF inhibitor was not known, Dr ...
TY - JOUR. T1 - Prognostic significance of high nuclear grade in patients with pathologic t1a renal cell carcinoma. AU - Suzuki, Kenjiro. AU - Mizuno, Ryuichi. AU - Mikami, Shuji. AU - Tanaka, Nobuyuki. AU - Kanao, Kent. AU - Kikuchi, Eiji. AU - Miyajima, Akira. AU - Nakagawa, Ken. AU - Oya, Mototsugu. PY - 2012/9/1. Y1 - 2012/9/1. N2 - Objective: A reliable prognostic indicator in patients with pathologic T1a renal cell carcinoma has not yet been fully elucidated. The aim of this study was to investigate the prognosis of pathologic T1a renal cell carcinoma cases with a special focus on pathological factors. Methods: The study population consisted of 338 patients diagnosed with solitary renal cell carcinoma at our hospital between 1996 and 2009. The relationship between disease progression and clinicopathologic features was analyzed retrospectively to determine if it affected recurrence and distant metastasis. Results: The Fuhrman nuclear grade distribution between the tumors was 1, 2, 3 and 4 ...
Preliminary data from an interim analysis of an ongoing phase III clinical trial of investigational temsirolimus (CCI-779) for the treatment of advanced renal cell carcinoma showed that single-agent therapy with temsirolimus significantly increased overall survival as a first-line treatment of patients with advanced disease and poor-risk features compared to interferon-alpha, a treatment for advanced renal cell carcinoma. In the trial, patients who were treated with temsirolimus alone experienced a 3.6-month, or 49%, increase in median overall survival time compared with patients treated with interferon-alpha alone (10.9 vs 7.3 months, P = .0069). 1
The bevacizumab experience in advanced renal cell carcinoma Lauren C Harshman, Sandy SrinivasDivision of Oncology, Stanford University School of Medicine, Stanford, California, USAAbstract: Bevacizumab in combination with interferon alfa is now approved for treatment-naïve advanced renal cell carcinoma (RCC) in both the US and Europe. Its objective response rates of 30% and progression-free survival rates of 9–10 months are ­comparable to the other approved first-line multityrosine kinase inhibitors, sunitinib and pazopanib. Its advantages include a different toxicity profile and assurance of ­administration compliance given its intravenous formulation. Enthusiasm for its use is blunted by the increased costs, the potential infusion-related reactions, the associated interferon-related toxicities, and the inconvenience of its nonoral formulation. Further study is warranted to assess its efficacy both as a single agent and in combination with the targeted agents and other
TY - JOUR. T1 - Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR). T2 - final results from a randomised, open-label, phase 3 trial. AU - Choueiri, Toni K.. AU - Escudier, Bernard. AU - Powles, Thomas. AU - Tannir, Nizar M.. AU - Mainwaring, Paul N.. AU - Rini, Brian I.. AU - Hammers, Hans J.. AU - Donskov, Frede. AU - Roth, Bruce J.. AU - Peltola, Katriina. AU - Lee, Jae Lyun. AU - Heng, Daniel Y C. AU - Schmidinger, Manuela. AU - Agarwal, Neeraj. AU - Sternberg, Cora N.. AU - McDermott, David F.. AU - Aftab, Dana T.. AU - Hessel, Colin. AU - Scheffold, Christian. AU - Schwab, Gisela. AU - Hutson, Thomas E.. AU - Pal, Sumanta. AU - Motzer, Robert J.. AU - METEOR investigators. PY - 2016/7/1. Y1 - 2016/7/1. N2 - Background Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR, and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of cabozantinib versus the mTOR inhibitor everolimus in patients with advanced renal cell carcinoma ...
BACKGROUND: The prognostic value of cyclooxygenase-2 (COX-2) in human renal cell carcinoma (RCC) remains unclear. The purposes of this study are to elucidate the clinical significance of COX-2 in clear cell RCC (CCRCC) and to assess the treatment effect of COX-2 inhibition on CCRCC cell lines. METHODS: Using tumor samples obtained from 137 patients who had undergone nephrectomy at Seoul National University Hospital, we evaluated COX-2 expression on immunohistochemistry. Moreover, we performed the cell proliferation assay using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-2H tetrazolium bromide (MTT) and cell invasion assay. Thus, we evaluated the effect of meloxicam, an inhibitor of COX-2, in two human CCRCC cell lines. RESULTS: Cancer-specific survival (p=0.038) and progression-free survival (p=0.031) were shorter in the COX-2 high expression group. A multivariate logistic regression model showed that COX-2 expression was an independent risk factor for pTNM stage and Fuhrman nuclear grade. The MTT ...
Adding "chemical shift" techniques to MRI can help differentiate clear cell renal cell carcinoma from other types of renal cell cancer, a new study shows. That differentiation can help physicians better determine treatment for these patients.. The study, conducted at Massachusetts General Hospital in Boston, included 156 patients with proven renal cell cancer. Clear cell renal carcinoma contains microscopic areas of fat, which is not seen on conventional imaging, said Dr. Azadeh Elmi, lead author of the study. "Chemical shift MRI enables us to quantify even small amounts of fat," she said. The study found that chemical shift MRI was about 83% accurate in differentiating clear cell renal cell carcinoma from other types of kidney cancer.. Clear cell type is the most common type of kidney cancer, and it has the greatest potential to metastasize, said Dr. Elmi. Chemical shift MRI is a protocol that can be readily performed in kidney MRI at no additional cost, she said. "As we are moving toward less ...
Patients with advanced renal cell carcinoma (RCC) are classified according to Memorial Sloan-Kettering Cancer Center (MSKCC) criteria in three risk-groups: favourable, intermediate and poor. To our knowledge there is only one study which examined the poor risk group (Hudes et al.), which led to the approval of temsirolimus in this population. However temsirolimus demonstrated a low response rate of 8.6% according to Response Evaluation Criteria In Solid Tumor (RECIST) criteria and a Progression free Survival (PFS) of 5.5 months and not all patients are suitable for temsirolimus treatment.. Thus, in clinical routine high-risk patients are also treated with multi Tyrosinkinase Inhibitors (mTKI). To date, a prospective data acquisition and control of effectiveness of a mTKI-treatment in high-risk patients has not been conducted.. Pazopanib was recently approved for the first-line treatment of advanced renal cell carcinoma in Europe and the USA. In the pivotal Phase III trial only nine patients in ...
TY - JOUR. T1 - Rising incidence of renal cell carcinoma in Ireland. AU - Falebita, Opeyemi A.. AU - Mancini, Silvia. AU - Kiely, Eamonn. AU - Comber, Harry. PY - 2009/3. Y1 - 2009/3. N2 - Objective: To determine the trend in the incidence of renal cell carcinoma in Ireland, and evaluate changes in the modes of presentation and outcomes. Methods: Data on all histologically diagnosed renal cancers in Ireland over a 12-year period (1994-2005) were retrieved from the database of the National Cancer Registry of Ireland. Data on all renal cancer deaths in Ireland in the period 1994-2004 were obtained from the Central Statistics Office. Results: There were 2,485 cases of renal cell carcinoma from 1994 to 2005, of which 64% were in males and 36% in females. The average age of females at diagnosis fell from 63 years in 1994 to 58 years in 2005, with little change in the average age in males. The age-adjusted incidence of renal cell carcinoma per 100,000 person-year increased from 5.2 in 1994 to 6.8 in ...
Thomas E. Hutson, Long H. Dang, Richard C. Lauer, Alexander Starodub, Ralph J. Hauke, Matt D. Galsky, Kathryn A. Bylow, Theodore Logan, Charles Lance Cowey, David C. Bibby, Gabriel Kremmidiotis, Elizabeth E. Doolin, Tina C. Lavranos, Guru Sonpavde, Noah M. Hahn, Christopher Sweeney, John Sarantopoulos. Phase I results of a phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients previously treated with VEGFR tyrosine kinase inhibitors. J Clin Oncol 30, 2012 (suppl; abstr 4603) http://www.asco.org/ASCOv2/Meetings/Abstracts&vmview=abst_detail_view&confID=114&abstractID=91911 ...
Cytoreductive nephrectomy has been an integral part of management in metastatic renal cell carcinoma for patients with good performance status, based on the benefit shown by prospective trials in the interferon era and retrospective trials in the targeted therapies era.
TY - JOUR. T1 - Association of microvascular and capillary-lymphatic invasion with outcome in patients with renal cell carcinoma. AU - Eisenberg, Manuel S.. AU - Cheville, John C.. AU - Thompson, R. Houston. AU - Kaushik, Dharam. AU - Lohse, Christine M.. AU - Boorjian, Stephen A.. AU - Costello, Brian. AU - Leibovich, Bradley C.. PY - 2013/7. Y1 - 2013/7. N2 - Purpose: We evaluated the association of microvascular and capillary-lymphatic invasion with patient outcome after nephrectomy for renal cell carcinoma. Materials and Methods: We identified 1,433 patients surgically treated for sporadic, unilateral renal cell carcinoma between 2001 and 2008. All specimens were reviewed by a single uropathologist for microvascular and capillary-lymphatic invasion. Associations with time to metastasis and death from renal cell carcinoma were evaluated using Cox proportional hazards models, controlling for established clinicopathological prognostic variables. Results: Microvascular invasion and ...
Epithelial-to-mesenchymal transition (EMT) is important in tumor invasiveness and metastasis. We aimed to determine prognostic value of six key EMT markers (CDH1, CDH2, SNAI1, SNAI2, VIM, TWIST1) in clear cell renal cell carcinoma (ccRCC). A total of 533 ccRCC patients with RNASeq data from The Cancer Genome Atlas (TCGA) cohort were included for analysis. Gene expression of these EMT markers was compared between tumor and normal tissues based on Oncomine database and TCGA cohort. Their correlations with progression-free survival (PFS) and overall survival (OS) were also examined in both TCGA cohort and FUSCC (Fudan University Shanghai Cancer Center) cohort. Cox proportional hazards regression model and Kaplan-Meier plot were used to assess the relative factors. Functional enrichment analyses were utilized to describe biologic function annotations and significantly involved hallmarks pathways of each gene. We found that Epithelial marker, CDH1 expression
Background: Caspase 4 (CASP4) dysregulation is related to the occurrence, development, and outcome of many malignant tumors, but its role in clear cell renal cell carcinoma (ccRCC) is unclear. This study was conducted to investigate the expression level of CASP4 in tumor tissu...
List of Tables. Number of Products under Development for Metastatic Renal Cell Carcinoma, H1 2015 12. Number of Products under Development for Metastatic Renal Cell Carcinoma-Comparative Analysis, H1 2015 13. Number of Products under Development by Companies, H1 2015 15. Number of Products under Development by Companies, H1 2015 (Contd..1) 16. Number of Products under Development by Companies, H1 2015 (Contd..2) 17. Number of Products under Investigation by Universities/Institutes, H1 2015 18. Comparative Analysis by Late Stage Development, H1 2015 19. Comparative Analysis by Clinical Stage Development, H1 2015 20. Comparative Analysis by Early Stage Development, H1 2015 21. Comparative Analysis by Unknown Stage Development, H1 2015 22. Products under Development by Companies, H1 2015 23. Products under Development by Companies, H1 2015 (Contd..1) 24. Products under Development by Companies, H1 2015 (Contd..2) 25. Products under Investigation by Universities/Institutes, H1 2015 26. Metastatic ...
X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 antagonists to improve immune cell trafficking to treat cancer and rare disease, today announced results from a pilot study of X4P-001-IO in combination with Opdivo (nivolumab) in patients with clear cell renal cell carcinoma who are non-responsive to the anti-PD-1 checkpoint inhibitor Opdivo alone.
Purpose: Temsirolimus is an effective treatment for renal cell carcinoma. It is associated with increases in serum cholesterol, triglyceride, and glucose. We investigated whether changes of these biomarkers could predict its efficacy. Experimental Design: We examined serial measurements of cholesterol, triglycerides, and glucose from patients randomized to IFN or temsirolimus in the Global Advanced Renal Cell Carcinoma Trial. Using time-dependent proportional hazards models, we quantified the association between changes in these biomarkers from baseline with overall survival (OS) and progression-free survival (PFS). We also assess the extent to which changes of these biomarkers predict the effects of temsirolimus on survival. Results: Temsirolimus was associated with larger mean increases in cholesterol (1.02 mmol/L; P | 0.0001), triglycerides (0.32 mmol/L; P = 0.0008), and glucose (1.28 mmol/L; P | 0.0001) compared with IFN and improved survival rate (OS: HR = 0.76, P = 0.02; PFS: HR = 0.70, P = 0
Clinical trial for Gastrointestinal Stroma Tumors | Carcinoma | Renal Cell | Mantle cell lymphoma | Advanced , Registry For Temsirolimus Sunitinib And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC) Mantle Cell Lymphoma (MCL) And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
New life-saving treatments for Mantle-cell | gastrointestinal stroma tumors | carcinoma | renal cell | lymphoma | advanced in clinical trial on Registry For Temsirolimus Sunitinib And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC) Mantle Cell Lymphoma (MCL) And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
Background Sunitinib has become mainstay first line treatment for patients with metastatic renal clear cell carcinoma (mRCC). Still, useful predictive markers of response are lacking and urgently needed for clinical decision making. Methods In the present study we investigated the predictive value of standard serum markers as well as clinical markers, including C-reactive protein (CRP), Neutrophil to Lymphocyte ratio (NLR) and early hypertension (eHTN) in an unselected prospective patient population treated with sunitinib for mRCC. Forty-six patients were enrolled in a prospective single-arm study of predictive markers for sunitinib response. Response rates according to RECIST 1.1 were used as primary end-point. Secondary objectives were to evaluate prognostic value of the candidate markers with regard to progression free survival (PFS) and overall survival (OS). In addition, toxicity rates and quality of life was recorded. Results Median PFS and OS was 9.1 months and 15.0 months, respectively. ...
The median age was 57 years (range 30-80). Most patients underwent a nephrectomy (n = 41; 70.7%), were male (n = 42; 72.4%) and had clear-cell (CC) RCC (n = 51; 87.9%). Patients were treated with first-line sunitinib (n = 45; 77.6%) or pazopanib (n = 13; 22.4%). The median time from the initial RCC diagnosis to the diagnosis of BMs was 9 months. The median time from the first occurrence of metastasis to the development of BMs was 7 months. The median overall survival (OS) of mRCC patients with BMs was 13 months. Time from the initial diagnosis of systemic metastasis to the development of BMs (,12 months; p = 0.001), histological subtype (non-CC; p,0.05) and number of BMs (≥2; p,0.05) were significantly associated with OS in multivariate analysis. There were no cases of toxic death. One mRCC patient with BMs (1.7%) experienced treatment-related cerebral necrosis. All other toxicities included those commonly observed with VEGF-TKI therapy.. ...
The FDA granted approval to nivolumab (Opdivo) for patients with renal cell carcinoma. Opdivo, a PD-1 inhibitor, was previously approved for the treatment of melanoma whose tumors express the BRAF V600 mutation as well as advanced non-small cell lung cancer.. About Renal Cell Carcinoma. Each year in the United States, more than 61,000 people are diagnosed with kidney cancer. The most common type of kidney cancer is renal cell carcinoma (RCC), which starts in the lining of very small tubes (tubules) in the kidney. For people with advanced RCC (cancer that has spread to other parts of the body), targeted therapies can play an important role in treatment. Approximately 20-30% of patients with RCC will have metastases at diagnosis and as many as 40% will demonstrate metastasis after primary surgical treatment for localized RCC. With a 5-year survival rate ranging from 5-10%, the prognosis for these patients is poor. About Opdivo. Opdivo is a precision cancer medicine that belongs to a new class of ...
This research study is comparing different drug combinations as a possible treatment for metastatic renal cell carcinoma (mRCC) and bone metastases. The names
Preoperative renal tumor subtype differentiation is definitely important for radiology and urology in clinical practice. vs 40.3180.4833 vs 50.0130.1654 vs 5 0.0010.411 Open in a separate window Note: 1: clear cell renal cell carcinoma; 2: papillary renal cell carcinoma; 3: chromophobic renal cell carcinoma; 4: uroepithelial carcinoma; 5: fat-poor angiomyolipoma. Open in a separate window Figure 3 Box-and-whisker plot of em K /em trans value. Boxes?=?interquartile range, whiskers?=?range of all values, horizontal line within box?=?median em K /em trans, ccRCC?=?clear cell RCC, pRCC?=?papillary RCC, cRCC?=?chromophobic RCC, UEC?=?uroepithelial carcinoma, fpAML?=?fat poor angiomyolipoma. Open in a separate window Figure 4 Box-and-whisker plot of em V /em e value. Boxes?=?interquartile range, whiskers?=?range of all values, horizontal line within box?=?median em V /em e, ccRCC?=?clear cell RCC, pRCC?=?papillary RCC, cRCC?=?chromophobic RCC, UEC?=?uroepithelial carcinoma, fpAML?=?fat poor ...
Basing on the symptoms of kidney cancer, the patients condition and the results of preliminary tests, the doctor chooses one or another method for diagnosing renal cell carcinoma to form the most objective image.. Treatment:. The treatment of renal cell carcinoma is based on several common methods used alone or in a complex manner. The attending physician, based on the type of tumor, the clinical stage of the age and the patients well-being, the available contraindications and other factors, may choose various methods of treatment.. The most effective way to treat renal cell carcinoma is surgical removal of the tumor. Radical nephrectomy is the complete removal of the affected kidney, usually along with the surrounding paranephric fiber, lymph nodes and sometimes the adrenal gland. If the tumor size does not exceed 7 cm, partial resection of the kidney is performed. There is also a laparoscopic method. In this case, the tumor is removed or resected with special instruments inserted into the ...